ISSN 0042-0018
Vol. 41, Issue 2, 2006January 01, 2006 PDT
FDA, CLIA, or a “Reasonable Combination of Both”: Toward Increased Regulatory Oversight of Genetic Testing
FDA, CLIA, or a “Reasonable Combination of Both”: Toward Increased Regulatory Oversight of Genetic Testing
Articles in Vol. 41, Issue 2, 2006
Vol. 41, Issue 2, 2006
- FDA, CLIA, or a "Reasonable Combination of Both": Toward Increased Regulatory Oversight of Genetic TestingDouglas A. Grimm
- Rhetoric of AcademeCurtis E. A. Karnow
- Executive Compensation: Reining in Runaway Abuses-AgainSusan Lorde Martin
- Caregivers in the Courtroom: The Growing Trend of Family Responsibilities DiscriminationJoan C. WilliamsStephanie Bornstein
- Indirect Sex Discrimination-A View from Across the PondJoanna Wade
- Carnero v. Boston Scientific Corporation: Interpreting the Extraterritorial Effect of the Civil Whistleblower Protection Provision of the Sarbanes-Oxley ActCaryn R. Nutt
- Process Theory and Emerging Thirteenth Amendment Jurisprudence:The Case of Agricultural GuestworkersBenjamin P. Quest
- Illinois Tool Works v. Independent Ink: Inking Out Limits of the Patent GrantTyler J. Gee
Douglas A. Grimm, FDA, CLIA, or a “Reasonable Combination of Both”: Toward Increased Regulatory Oversight of Genetic Testing, 41 U.S.F. L. Rev. 1 (2006).